Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

The phase 3 KEYNOTE-412 study (NCT03040999), pembro  + CRT (pembro arm) showed a trend toward improved EFS vs placebo + CRT (pbo arm) in pts with LA HNSCC, although the difference was not statistically significant (HR, 0.83 [95% CI, 0.68-1.03]; P=0.0429 [superiority threshold, P=0.0242]). Prespecified HRQoL outcomes from KEYNOTE-412 are prese nted.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.P. Machiels, Y. TAO, B. Burtness, M. Tahara, D. Rischin, G.V. Alves, I.P. Figueiredo Lima, B.G.M. Hughes, Y. Pointreau, S. Aksoy, S. Laban, R. Greil, M. Burian, M. Hetnal, L. Licitra, C.M. Black, J. Norquist, B. Gumuscu, B. Bidadi, L.L. Siu Tags: 156 Source Type: research